Loading...
OTCM
ODTCD
Market cap164bUSD
, Last price  
USD
Name

Odonate Inc

Chart & Performance

D1W1MN
P/E
—
P/S
—
EPS
6.68
Div Yield, %
—
Shrs. gr., 5y
125.79%
Rev. gr., 5y
%
Revenues
0k
Net income
7m
-82.94%
-158,000-3,085,000-32,744,000-88,960,000-108,720,000-126,350,000-68,315,00042,940,0007,325,000
CFO
9m
+386.91%
-165,000-1,733,000-25,858,000-67,094,000-96,638,000-113,130,000-75,725,0001,795,0008,740,000

Profile

Odonate Therapeutics, Inc., a pharmaceutical company, develops therapeutics for the treatment of cancer. It is developing tesetaxel, an orally administered chemotherapy agent, which is in Phase III clinical study for patients with metastatic breast cancer. The company was founded in 2013 and is based in New York, New York.
URL
https://www.odonate.com/
IPO date
Dec 07, 2017
Employees
137
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
21
342
Unusual Expense (Income)
NOPBT
(21)
(342)
NOPBT Margin
Operating Taxes
2,119
(33,302)
Tax Rate
NOPAT
(2,140)
32,960
Net income
7,325
-82.94%
42,940
-162.86%
Dividends
Dividend yield
Proceeds from repurchase of equity
(1,620)
BB yield
Debt
Debt current
504
469
Long-term debt
3,590
2,299
Deferred revenue
Other long-term liabilities
26
Net debt
(74,383)
(67,022)
Cash flow
Cash from operating activities
8,740
1,795
CAPEX
Cash from investing activities
20,150
(58,345)
Cash from financing activities
(196)
(1,620)
FCF
(2,083)
35,664
Balance
Cash
57,019
48,204
Long term investments
21,458
21,586
Excess cash
78,477
69,790
Stockholders' equity
(384,250)
(391,444)
Invested Capital
494,696
495,061
ROIC
6.64%
ROCE
EV
Common stock shares outstanding
2,870
Price
28,000.00
29.63%
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT